Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting ATR in patients with cancer
Natalie Ngoi, Patrick G. Pilié, Daniel J. McGrail, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 278-293
Closed Access | Times Cited: 24

Showing 24 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Xin Li, Lee Zou
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 13
KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency
Samah W. Awwad, Colm Doyle, Josie Coulthard, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma
James Stewart, Dragomir B. Krastev, Rachel Brough, et al.
Oncogene (2025)
Open Access | Times Cited: 1
Synthetic lethal strategies for the development of cancer therapeutics
Natalie Ngoi, David Gallo, C. Sevillano, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 4
PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells
Kimiyoshi Yano, Megumi Kato, Satoshi Endo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing’s sarcoma cells
Judy Ziener, Julián Henao‐Restrepo, Johanna Leonhardi, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis
Shen-Nan Shi, Qiuyang Xu, Xiaofei Jiao, et al.
Biochemical Pharmacology (2025), pp. 116949-116949
Closed Access
Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells
Francis M. Barnieh, Goreti Ribeiro Morais, Paul M. Loadman, et al.
Advanced Science (2024)
Open Access | Times Cited: 3
Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor
Meng Wu, Xiaofang Chen, Haoran Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Impact of radiation therapy on the immunological tumor microenvironment
Emma Guilbaud, Flavie Naulin, Lydia Meziani, et al.
Cell chemical biology (2025)
Closed Access
Discovery of Novel and Highly Potent Anticancer Agents Enabled by Selenium Scanning of Noscapine
Defeng Li, Shuting Shen, Chuanxu Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 293, pp. 117714-117714
Closed Access
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors
Vito Amodio, Pietro Paolo Vitiello, Alberto Bardelli, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 2
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers
Christopher L. Carroll, Michael G. Johnson, Yanbing Ding, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies
Zhi Liu, Kailong Jiang, Yan Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 12735-12759
Closed Access | Times Cited: 1
Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence
Fatemeh Moosavi, Bahareh Hassani, Somayeh Nazari, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189185-189185
Closed Access | Times Cited: 1
Unveiling Commonalities: Exploring Shared Characteristics in Clear Cell Carcinomas of the Gynecologic Tract
Félix Blanc‐Durand, Natalie Ngoi, Diana Lim, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 20, pp. 4557-4565
Closed Access | Times Cited: 1
Long-Term Survivor of Intrahepatic Cholangiocarcinoma for over 18 Years: Case Study with Longitudinal Histo-molecular and Tumor Immune Microenvironment Characterization and Systematic Review of the Literature
Paola Mattiolo, Mario De Bellis, Andrea Mafficini, et al.
Journal of Gastrointestinal Cancer (2024) Vol. 55, Iss. 4, pp. 1634-1646
Open Access | Times Cited: 1
FET fusion oncoproteins disrupt physiologic DNA repair networks in cancer
Shruti Menon, Daniel Esguerra Gracilla, Marcus R. Breese, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
Yaniv Kazansky, Helen S. Mueller, Daniel Cameron, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells
Judy Ziener, Julián Henao‐Restrepo, Johanna Leonhardi, et al.
Research Square (Research Square) (2024)
Open Access
Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer
Angela M. Schab, Amanda Compadre, Richard Drexler, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Beginning at the ends: telomere and telomere-based cancer therapeutics
Zahra Sadr, Masoumeh Ghasemi, Soheyla Jafarpour, et al.
Molecular Genetics and Genomics (2024) Vol. 300, Iss. 1
Closed Access
ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer
Jung Won Chun, Hye Won Shon, Jeong Eun Gong, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024), pp. 167625-167625
Closed Access
Page 1

Scroll to top